Iain Bressendorff1,2, Ditte Hansen2, Morten Schou3, Andreas Pasch4,5, Lisbet Brandi6. 1. Department of Cardiology, Nephrology, and Endocrinology, Nordsjællands Hospital, Hillerod, Denmark; iain@bressendorff.com. 2. Departments of Nephrology and. 3. Cardiology, Herlev and Gentofte Hospital, Herlev, Denmark. 4. Department of Biomedical Research, University of Bern, Bern, Switzerland; and. 5. Calciscon AG, Bern, Switzerland. 6. Department of Cardiology, Nephrology, and Endocrinology, Nordsjællands Hospital, Hillerod, Denmark.
Abstract
BACKGROUND AND OBJECTIVES:Serum calcification propensity is a novel functional test that quantifies the functionality of the humeral system of calcification control. Serum calcification propensity is measured by T50, the time taken to convert from primary to secondary calciprotein particle in the serum. Lower T50 represents higher calcification propensity and is associated with higher risk of cardiovascular events and death in patients with ESKD. Increasing magnesium in serum increases T50, but so far, no clinical trials have investigated whether increasing serum magnesium increases serum calcification propensity in subjects with ESKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a single-center, randomized, double-blinded, parallel group, controlled clinical trial, in which we examined the effect of increasing dialysate magnesium from 1.0 to 2.0 mEq/L for 28 days compared with maintaining dialysate magnesium at 1.0 mEq/L on T50 in subjects undergoing hemodialysis for ESKD. The primary end point was the value of T50 at the end of the intervention. RESULTS:Fifty-nine subjects were enrolled in the trial, and of these, 57 completed the intervention and were analyzed for the primary outcome. In the standard dialysate magnesium group, T50 was 233±81 minutes (mean±SD) at baseline (mean of days -7 and 0) and 229±93 minutes at follow-up (mean of days 21 and 28), whereas in the high dialysate magnesium group, T50 was 247±69 minutes at baseline and 302±66 minutes at follow-up. The difference in T50 between the two groups at follow-up (primary analysis) was 73 minutes (between-group difference; 95% confidence interval, 30 to 116; P<0.001), and the between-group difference in serum magnesium was 0.88 mg/dl (95% confidence interval, 0.66 to 1.10; P=0.001). CONCLUSIONS: Increasing dialysate magnesium increases T50 and hence, decreases calcification propensity in subjects undergoing maintenance hemodialysis. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_08_21_CJASNPodcast_18_9_B.mp3.
RCT Entities:
BACKGROUND AND OBJECTIVES: Serum calcification propensity is a novel functional test that quantifies the functionality of the humeral system of calcification control. Serum calcification propensity is measured by T50, the time taken to convert from primary to secondary calciprotein particle in the serum. Lower T50 represents higher calcification propensity and is associated with higher risk of cardiovascular events and death in patients with ESKD. Increasing magnesium in serum increases T50, but so far, no clinical trials have investigated whether increasing serum magnesium increases serum calcification propensity in subjects with ESKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a single-center, randomized, double-blinded, parallel group, controlled clinical trial, in which we examined the effect of increasing dialysate magnesium from 1.0 to 2.0 mEq/L for 28 days compared with maintaining dialysate magnesium at 1.0 mEq/L on T50 in subjects undergoing hemodialysis for ESKD. The primary end point was the value of T50 at the end of the intervention. RESULTS: Fifty-nine subjects were enrolled in the trial, and of these, 57 completed the intervention and were analyzed for the primary outcome. In the standard dialysate magnesium group, T50 was 233±81 minutes (mean±SD) at baseline (mean of days -7 and 0) and 229±93 minutes at follow-up (mean of days 21 and 28), whereas in the high dialysate magnesium group, T50 was 247±69 minutes at baseline and 302±66 minutes at follow-up. The difference in T50 between the two groups at follow-up (primary analysis) was 73 minutes (between-group difference; 95% confidence interval, 30 to 116; P<0.001), and the between-group difference in serum magnesium was 0.88 mg/dl (95% confidence interval, 0.66 to 1.10; P=0.001). CONCLUSIONS: Increasing dialysate magnesium increases T50 and hence, decreases calcification propensity in subjects undergoing maintenance hemodialysis. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_08_21_CJASNPodcast_18_9_B.mp3.
Authors: Andreas Pasch; Stefan Farese; Steffen Gräber; Johanna Wald; Walter Richtering; Jürgen Floege; Willi Jahnen-Dechent Journal: J Am Soc Nephrol Date: 2012-09-06 Impact factor: 10.121
Authors: Charlotte A Keyzer; Martin H de Borst; Else van den Berg; Willi Jahnen-Dechent; Spyridon Arampatzis; Stefan Farese; Ivo P Bergmann; Jürgen Floege; Gerjan Navis; Stephan J L Bakker; Harry van Goor; Ute Eisenberger; Andreas Pasch Journal: J Am Soc Nephrol Date: 2015-04-29 Impact factor: 10.121
Authors: D O Dahle; A Åsberg; A Hartmann; H Holdaas; M Bachtler; T G Jenssen; M Dionisi; A Pasch Journal: Am J Transplant Date: 2015-09-16 Impact factor: 8.086
Authors: Parisa Aghagolzadeh; Matthias Bachtler; Rakesh Bijarnia; Christopher Jackson; Edward R Smith; Alex Odermatt; Ramin Radpour; Andreas Pasch Journal: Atherosclerosis Date: 2016-05-27 Impact factor: 5.162
Authors: Juan M Diaz-Tocados; Alan Peralta-Ramirez; María E Rodríguez-Ortiz; Ana I Raya; Ignacio Lopez; Carmen Pineda; Carmen Herencia; Addy Montes de Oca; Noemi Vergara; Sonja Steppan; M Victoria Pendon-Ruiz de Mier; Paula Buendía; Andrés Carmona; Julia Carracedo; Juan F Alcalá-Díaz; Joao Frazao; Julio M Martínez-Moreno; Antonio Canalejo; Arnold Felsenfeld; Mariano Rodriguez; Escolástico Aguilera-Tejero; Yolanda Almadén; Juan R Muñoz-Castañeda Journal: Kidney Int Date: 2017-07-29 Impact factor: 10.612
Authors: Luca Zanoli; Paolo Lentini; Marie Briet; Pietro Castellino; Andrew A House; Gerard M London; Lorenzo Malatino; Peter A McCullough; Dimitri P Mikhailidis; Pierre Boutouyrie Journal: J Am Soc Nephrol Date: 2019-04-30 Impact factor: 10.121
Authors: Joshua D Bundy; Xuan Cai; Rupal C Mehta; Julia J Scialla; Ian H de Boer; Chi-Yuan Hsu; Alan S Go; Mirela A Dobre; Jing Chen; Panduranga S Rao; Mary B Leonard; James P Lash; Geoffrey A Block; Raymond R Townsend; Harold I Feldman; Edward R Smith; Andreas Pasch; Tamara Isakova Journal: Clin J Am Soc Nephrol Date: 2019-10-28 Impact factor: 8.237
Authors: Peter Lanzer; Fadil M Hannan; Jan D Lanzer; Jan Janzen; Paolo Raggi; Dominic Furniss; Mirjam Schuchardt; Rajesh Thakker; Pak-Wing Fok; Julio Saez-Rodriguez; Angel Millan; Yu Sato; Roberto Ferraresi; Renu Virmani; Cynthia St Hilaire Journal: J Am Coll Cardiol Date: 2021-09-14 Impact factor: 27.203
Authors: Wei Chen; Jessica Fitzpatrick; Jose M Monroy-Trujillo; Stephen M Sozio; Bernard G Jaar; Michelle M Estrella; Jishyra Serrano; Viktoriya Anokhina; Benjamin L Miller; Michal L Melamed; David A Bushinsky; Rulan S Parekh Journal: Am J Kidney Dis Date: 2020-08-13 Impact factor: 8.860